Phase 2/3Recruiting

Open-label, Long-term Safety, Efficacy, and Pharmacokinetics Study of Vibegron in Pediatric Subjects 2 Years to < 18 Years of Age With NDO and on CIC (KANGUROO)

A Phase 2/3, Open-label, Baseline-controlled, Multicenter, Long-term Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Vibegron in Pediatric Subjects 2 Years to < 18 Years of Age With Neurogenic Detrusor Overactivity (NDO) on Clean Intermittent Catheterization (CIC)

Sponsor
Urovant Sciences GmbH (Industry)
Enrollment
71 planned
Conditions
Neurogenic Detrusor Overactivity
Interventions
Vibegron
Ages
children
Registry
NCT05491525

Full record on ClinicalTrials.gov

From the registry

The purpose of this study is to evaluate the safety, efficacy, and PK of Vibegron in pediatric participants with NDO who are regularly using CIC

Primary outcomes

  • Change from Baseline in maximum cystometric capacity (MCC) based on bladder filling urodynamics

History

  1. Study completion expected

  2. Primary completion expected

  3. Last registry update

  4. Started

  5. Registered